Page 204 - Eceptor News Today

The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about the detrimental effects of antibodies. Antibody-dependent enhancement (ADE) of infection is one of the biggest concerns in terms of not only the antibody reaction to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon reinfection with the virus but also the reaction to COVID-19 vaccines.

As SARS-CoV-2 continues to evolve, new variants are expected to arise that may have an increased ability to infect their hosts and evade the hosts' immune systems.

In the current study, researchers investigate the transplacental transmission of antibodies in vaccinated pregnant women.

Mark Bear, Picower Professor of Neuroscience at MIT, recalls the "eureka moment" 20 years ago when he realized that a severe developmental brain disorder -;fragile X syndrome-;might be treated with drugs that inhibit a neurotransmitter receptor called mGluR5.

Researchers explore the germinal cell responses in both healthy individuals and kidney transplant patients in their recent study.

A new study reveals that scientists have found three viruses in bats in Laos that exhibit similar characteristic features as SARS-CoV-2.

Researchers in Singapore have conducted a study showing active replication of a human coronavirus in bats that occurred without the viral spike protein binding to host cell receptors.

Oncotarget published "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.

Researchers from the Genos Glycoscience Research Laboratory in Croatia have recently investigated the sites that the S protein is capable of binding with.

There remains a significant need for new and effective drugs that can be used to treat COVID-19.